Dabigatran
 |
|
| Clinical data | |
|---|---|
| Trade names | Pradaxa, Pradax, Prazaxa |
| License data |
|
| Pregnancy category |
|
| Routes of administration |
oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 3–7% |
| Protein binding | 35% |
| Biological half-life | 12–17 hours |
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C34H41N7O5 |
| Molar mass | 627.734 g/mol |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?)
|
|
Dabigatran (Pradaxa, Prazaxa) is an anticoagulant medication that can be taken by mouth. It is being studied for various uses and in some cases is an alternative to warfarin, since it does not have to be monitored by blood tests, but offers similar results in terms of efficacy.
In case of major bleeding, there is an antidote, idarucizumab (sold under the brand name Praxbind). A large study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation by dabigatran within minutes.
It is in the class of a direct thrombin inhibitor. It was developed by the pharmaceutical company Boehringer Ingelheim.
Dabigatran is used to prevent strokes in those with atrial fibrillation not caused by heart valve issues, as well as deep vein thrombosis and pulmonary embolism in persons who have been treated for 5–10 days with parenteral anticoagulant (usually low molecular weight heparin), and to prevent deep vein thrombosis and pulmonary embolism in some circumstances.
It appears to be as effective as warfarin in preventing nonhemorrhagic strokes and embolic events in those with atrial fibrillation not due to valve problems.
Dabigatran is contraindicated in patients who have active pathological bleeding, since dabigatran can increase bleeding risk and can also cause serious and potentially life-threatening bleeds. Dabigatran is also contraindicated in patients who have a history of serious hypersensitivity reaction to dabigatran (e.g. anaphylaxis or anaphylactic shock). The use of dabigatran should also be avoided in patients with mechanical prosthetic heart valve due to the increased risk of thromboembolic events (e.g. valve thrombosis, stroke, and myocardial infarction) and major bleeding associated with dabigatran in this population.
...
Wikipedia